Daily Nation examines fundraising efforts in Kenya to support patients living with HIV/AIDS

The Daily Nation examines efforts underway in Kenya to raise money for patients living with HIV/AIDS who are in need antiretroviral (ARV) therapy. 

According to the newspaper, a team of experts is examining alternative sources to pay for HIV/AIDS treatment, including the possibility of adding additional taxes to cellular phone air-time, alcohol, cigarettes and airplane tickets, encouraging individuals and businesses to contribute to the cost of treatment for an individual patient, and "public-private partnerships with local pharmaceutical companies to produce drugs and sell to the government at a cheaper price."

Of the estimated 1.4 million people believed to be infected with HIV/AIDS, "the Government is providing ARVs to 360,000 of them," the Daily Nation writes. The article examines several reasons the country is facing a funding shortfall to cover patients living with HIV/AIDS and additional fundraising ideas to help close the gap (Okwemba, 3/29).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New insights into the mechanisms of efavirenz-induced neurotoxicity